Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

Table 1 Baseline patient characteristics

	PF-ILD (n = 14,413)
Sex, n (%)
Female	6934 (48.1)
Mean age, years (SD)	68.4 (15.0)
Median duration of follow-up, years (IQR)	1.7 (0.4–3.8)
Subtype of PF-ILD, n (%)
Exposure-related ILD other than hypersensitivity pneumonitis^a	3486 (24.2)
Idiopathic interstitial pneumonia	3113 (21.6)
Hypersensitivity pneumonitis	728 (5.1)
Autoimmune ILD
RA-ILD	2521 (17.5)
SSc-ILD	907 (6.3)
MCTD-ILD	655 (4.5)
Other autoimmune^b	1503 (10.4)
Sarcoidosis-ILD	1500 (10.4)

Baseline was defined as the date of progression
ILD interstitial lung disease, IQR interquartile range, MCTD mixed connective tissue disease, PF-ILD progressive fibrosing interstitial lung disease, RA rheumatoid arthritis, SD standard deviation, SSc systemic sclerosis
^aCoal workers’ pneumoconiosis (n = 144), asbestosis (n = 878), pneumoconiosis due to other dust containing silica (n = 399), aluminosis of the lung (n = 1), bauxite fibrosis of the lung (n = 13), berylliosis (n = 8), graphite fibrosis of the lung (n = 28), siderosis (n = 25), pneumoconiosis due to other specified inorganic dusts (n = 19), unspecified pneumoconiosis (n = 130), byssinosis (n = 2), cannabinosis (n = 1), bronchitis and pneumonitis due to chemicals, gases, fumes and vapours (n = 42), chronic respiratory conditions due to chemicals, gases, fumes and vapours (n = 119), chronic and other pulmonary manifestations due to radiation (n = 450), chronic drug-induced interstitial lung disorders (n = 454), unspecified drug-induced interstitial lung disorders (n = 638), respiratory conditions due to other specified external agents (n = 46), respiratory conditions due to unspecified external agent (n = 89)
^bSjogren syndrome (n = 804), polymyositis (n = 435) and systemic lupus erythematosus (n = 264)

ISSN: 1465-993X